{"id":"tacrolimus-reddy-laboratory","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Nephrotoxicity"},{"rate":"20-40","effect":"Hypertension"},{"rate":"10-25","effect":"Hyperglycemia/new-onset diabetes"},{"rate":"5-15","effect":"Neurotoxicity (tremor, headache)"},{"rate":"15-30","effect":"Infections"},{"rate":"5-15","effect":"Hyperkalemia"},{"rate":"5-10","effect":"Gum hyperplasia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tacrolimus binds to the immunophilin FKBP12, and this complex inhibits calcineurin, a serine/threonine phosphatase essential for T-cell receptor signaling. By blocking calcineurin, tacrolimus prevents dephosphorylation and nuclear translocation of NFAT, thereby suppressing the transcription of IL-2 and other cytokines required for T-cell proliferation and immune response.","oneSentence":"Tacrolimus inhibits calcineurin phosphatase, blocking T-cell activation and proliferation by preventing nuclear translocation of NFAT transcription factors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:11:00.148Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Organ transplant rejection prophylaxis (kidney, heart, liver, pancreas)"},{"name":"Atopic dermatitis"},{"name":"Severe rheumatoid arthritis"},{"name":"Autoimmune uveitis"}]},"trialDetails":[{"nctId":"NCT02014103","phase":"PHASE4","title":"Conversion From Brand to Generic Tacrolimus in High Risk Transplant Recipients","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2015-03","conditions":"Complication of Transplant","enrollment":71}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Reddy's Laboratory tacrolimus"],"phase":"marketed","status":"active","brandName":"Tacrolimus, Reddy Laboratory","genericName":"Tacrolimus, Reddy Laboratory","companyName":"University of Cincinnati","companyId":"university-of-cincinnati","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tacrolimus inhibits calcineurin phosphatase, blocking T-cell activation and proliferation by preventing nuclear translocation of NFAT transcription factors. Used for Organ transplant rejection prophylaxis (kidney, heart, liver, pancreas), Atopic dermatitis, Severe rheumatoid arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}